Long noncoding RNAs (lncRNAs) are being increasingly recognized as major players in governing fundamental 21 biological processes through diverse mechanisms. Maternally expressed gene 3 (MEG3) is an imprinted gene 22 located at 14q32 that encodes a lncRNA correlated with several human cancers. Recently, the methylation-23 dependent downregulation of MEG3 has been described in liver cancers. However, its biological functional role 24 in liver fibrosis remains unknown. In our study, MEG3 levels were remarkably decreased in CCl 4 -induced 25 mouse liver fibrosis models and human fibrotic livers as demonstrated by real-time quantitative PCR. Moreover, 26 the expression of MEG3 was downregulated in human hepatic stellate cell lines LX-2 cells in response to 27 transforming growth factor-β1 (TGF-β1) stimulation in dose and time-dependent manner. Enforced expression 28 of MEG3 in LX-2 cells inhibited TGF-β1-induced cell proliferation, while promoting cell apoptosis. In addition, 29 hypermethylation of MEG3 promoter was identified by methylation-specific PCR and MEG3 expression was 30 robustly increased by the inhibition of methylation with either 5-aza-2-deoxycytidine (5-azadC), or siRNA to 31 DNA methyltransferase 1 (DNMT1) in TGF-β1-induced LX-2 cells. More importantly, overexpression of MEG3 32 could activate p53 and mediate cytochrome c release, subsequently leading to caspase-3-dependent apoptosis 33 in TGF-β1-treated LX-2 cells. These findings suggested that MEG3 may play an important role in stellate cell 34 activation and liver fibrosis progression and act as a novel potential therapeutic target for liver fibrosis. 
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44
Following chronic liver injury of any cause, hepatic stellate cells (HSCs) factor-β1 (TGF-β1) and platelet-derived growth factor (PDGF) [3] . It is 50 well accepted that activation of HSCs is a pivotal event during liver 51 fibrogenesis [4] [5] [6] . However, better figuring out the mechanisms of HSC 52 activation is still beyond our reach because of its complexity.
53
Regulatory noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), 54 a great variety of long noncoding RNAs (lncRNAs), play increasingly key 55 roles in the development of human diseases [7] [8] [9] [10] . LncRNA is commonly 56 defined as a RNA molecular which is larger than 200 nucleotides (nt) 57 with limited or no protein-coding capacity [11, 12] . A large and growing 58 body of literature shows that involvement of lncRNAs in liver diseases, 59 and in liver cancers in particular [10, 13] . For example, a lncRNA, down- 
Small interfering RNAs and transfection

170
The cells were cultured in serum-free DMEM for 12 h. On the day of 171 transfection, the cells were plated in DMEM supplemented with 10%
172
FBS at a density of 2-3 × 10 5 cells/ml and were transfected with protocol. The culture medium was changed 6 h after transfection, and
176
TGF-β1 (Peprotech, USA) was added at a concentration of 10 ng/ml.
177
The sequences of oligonucleotides used are as follows: siRNA-DNMT1: were transfected with pCI-MEG3, siRNA-DNMT1 or negative control.
187
The culture medium was changed 6 h after transfection, and TGF-β1
188
(Peprotech, USA) was added at a concentration of 10 ng/ml. Cruz, USA) was used at 1:600 as was anti-β-actin (Santa Cruz, USA).
255
Horseradish peroxidase conjugated anti-mouse and anti-rabbit anti- (Fig. 1b, c) . Real-time qPCR result showed that MEG3 was progres-307 sively downregulated as liver fibrosis progressed (Fig. 1d) . livers as shown by Immunohistochemical and western blot (Fig. 2b, c ).
317
Interestingly, MEG3 was also downregulated in human liver fibrotic 318 tissues compared with the control liver tissues (Fig. 2d) . (Fig. 3a) . The expression of α-SMA protein was also increased (Fig. 3c, d) . These results indicated that (Fig. 4a) . Firstly, we investigated the effects of overex- (Fig. 4b) . that induced by transfection of pCI-control (Fig. 4c) . Besides, overexpres- G1 phase and decrease the population of cells in S phases (Fig. 4d) . (Fig. 5a ). Important-374 ly, treatment of LX-2 cells with TGF-β1 (10 ng/ml) significantly induced 375 hypermethylation of the MEG3 gene (Fig. 5b) . These results indicated increased in TGF-β1-treated LX-2 cells (Fig. 5b, c) . More importantly, 385 exposure with 5-azadC also diminished TGF-β1-mediated upregulation 386 of α-SMA and Col1A1 mRNA and protein expression (Fig. 5d, e) . In (Fig. 6a) , which was further confirmed by western blot (Fig. 6b ). More-397 over, treatment with TGF-β1 (10 ng/ml) markedly induced upregulated 398 expression of DNMT1 mRNA and protein in LX-2 cells (Fig. 6c) . Next, to suppressed DNMT1 mRNA and protein expression (Fig. 6d) . Further-404 more, introduction of DNMT1 siRNA caused a significant inhibition of 405 cell proliferation in TGF-β1-treated LX-2 cells (Fig. 6e) . Importantly, were observed in cells incubated with siRNA to DNMT1 (Fig. 6f) . More LX-2 cells compared with control siRNA-tranfected cells (Fig. 6g) .
411
These data indicated that MEG3 expression could be modulated by with the control (Fig. 7a) . Next, we measured the signaling marker pro- (Fig. 7d) . Moreover, pifithrin-μ, the (Fig. 7e, f) . DNA methylation leading to aberrant expression of MEG3 RNA [19] . 
483
In this study, we found that the expression of MEG3 was consistently to some extent in non-CpG sequences in embryonic stem cells [48, 49] .
509
DNA methylation is currently the most widely studied epigenetic mod- daughter strand after DNA methylation [52] . In recent study, we found 
that the level of DNMT1 expression was analyzed via immunofluores-527 cence staining in control liver tissues and liver fibrotic tissues. The result 528 suggested that more nuclear DNMT1 labeling in livers of rats that had 529 received CCl 4 as compared to control livers [53] . More importantly, 530 our previous study also revealed that TGF-β1 treatment markedly 531 induced nuclear translocation of DNMT1 and upregulated expression 532 of DNMT1 in hepatic stellate cells [54, 55] . In particular, it has been pos- lectively activate p53 target genes [29, 58, 59 ]. In our study, we found that and caspase activation [33, 35, 62, 63] . Herein, we found that overexpres- 
